RecruitingNCT07021742

BioHealx® Anal Fistula Device Post Market Surveillance Study


Sponsor

Signum Surgical USA Inc.

Enrollment

50 participants

Start Date

Jun 14, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Age 18 - 75 years
  • Presence of Single Continuous Anal Fistula presenting for initial curative surgery
  • Failed or Recurrent Anal Fistula Closure
  • Minimum of 6-weeks of draining seton placed prior to procedure.
  • Availability for follow-up contacts and willingness to complete the Informed Consent.

Exclusion Criteria19

  • Fistula tract shorter than 2cm
  • Complex fistula tract (branching)
  • Body Mass Index > 35
  • Known uncontrolled diabetes or other systemic condition associated with impaired healing
  • Known HIV-positive or immunocompromised
  • Rectal prolapse
  • Pregnancy
  • Rectal / fistula malignancy
  • Crohn's disease
  • Ulcerative proctitis
  • Hidradenitis suppurativa of the anal region
  • Pilonidal sinus disease
  • Presence of hemorrhoid Involving fistula site
  • Continuous use of anti-inflammatory
  • Intersphincteric fistula in ano or fistula treatable by simple fistulotomy
  • Active infection or abscess involving fistula site
  • Known allergy to PLGA material
  • Any severe acute or uncontrolled chronic disease that according to the investigator might render the patient unsuitable for the study
  • Treatment with an investigational drug or medical device in the past 30 days

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBioHealx

Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.


Locations(5)

The Colorectal Institute

Fort Myers, Florida, United States

Weill Cornell Medicine

New York, New York, United States

Northwell Health

Staten Island, New York, United States

Maininle Health Lankenau

Bryn Mawr, Pennsylvania, United States

Geisinger

Danville, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07021742


Related Trials